ClinicalTrials.gg
TerminatedNCT03809039Updated Dec 31, 2025Results posted

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-6345 in Healthy Subjects

A Phase 1 interventional study of MT-6345 and MT-6345 Placebo in Healthy, sponsored by Tanabe Pharma America, Inc.. Terminated at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by Tanabe Pharma America, Inc. (part of Tanabe Pharma Corporation) · Phase 1, Interventional, and Other

How we know

Why this study was terminated
Preclinical finding

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to Investigate the Safety, Tolerability and Pharmacokinetics of MT-6345 in Healthy Subjects.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Tanabe Pharma America, Inc. is the lead sponsor of 13 studies on the registry; 1 is open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Additional screening criteria check may apply for qualification:

  • Able to provide written to participate in this study after reading the participant information sheet and Informed Consent Form (ICF), and after having the opportunity to discuss the study with the Investigator or designee.
  • Healthy and free from illness or disease as determined by medical history, physical examination, laboratory and other tests at Screening and Day -1.
  • A body weight of ≥60 kg for males and ≥50 kg for females and a (BMI) (Quetelet index) ranging from 18 to 30.0 kg/m2 inclusive at Screening and Day -1.
  • In the Investigator's opinion, subject is able to understand the nature of the study and any risks involved in participation, and willing to cooperate and comply with the Protocol restrictions and requirements.

Exclusion criteria

Exclusion Criteria:

Additional screening criteria check may apply for qualification:

  • Subjects with (in the opinion of the Investigator) endocrine, thyroid, hepatic, respiratory, gastrointestinal, neurological, renal, cardiovascular disease, or history (within the last 5 years) of any significant psychiatric/psychotic illness disorder (including anxiety, depression and reactive depression).
  • Female subjects who are pregnant (positive pregnancy test at Screening or Day -1) or lactating.
  • Having previously received MT-6345 as part of this study.
  • Clinically relevant abnormal medical history, physical findings or laboratory values at Screening or Day -1 that could interfere with the objectives of the study or the safety of the subject, as judged by the Investigator.
  • Subjects who test positive for surface antigen, hepatitis B core antibody, antibody, (HIV)-1 or HIV-2 antibodies at Screening.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Single Ascending Dose: MT-6345 & Placebo

    Drug: MT-6345 · Drug: MT-6345 Placebo

  • Experimental
    Multiple Ascending Dose: MT-6345 & Placebo

    Drug: MT-6345 · Drug: MT-6345 Placebo

Interventions

  • DrugMT-6345

    MT-6345

  • DrugMT-6345 Placebo

    MT-6345 Placebo

06

What researchers measure

Primary outcomes

  1. Number of Participants With Mild, Moderate and Severe Adverse Events

    The criteria of Mild, Moderate and Severe are as follows: Mild: The event is transient and easily tolerated by the subject. Moderate: The event causes discomfort and interferes with the subject's general condition. Severe: The event causes considerable interference with the subject's general condition and may be incapacitating.

    Time frame: Up to 6 weeks

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax) of MT-6345

    Cmax was measured for MT-6345 for the PK analysis set (PKPOP) subjects in Part 1 and Part 2, and on Day 1 in Part 3.

    Time frame: Part 1 and Part 2: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72 (Day 4), 120 (Day 6), 192 (Day 9), and 336 (Day 15 Follow-up Visit) hours. Part 3: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours.

  2. Time to Maximum Plasma Concentration (Tmax) of MT-6345

    Tmax was measured for MT-6345 for the PKPOP subjects in Part 1 and Part 2, and on Day 1 in Part 3.

    Time frame: Part 1 and Part 2: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72 (Day 4), 120 (Day 6), 192 (Day 9), and 336 (Day 15 Follow-up Visit) hours. Part 3: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours.

  3. Plasma Terminal Elimination Half Life (t½) of MT-6345

    t1/2 was measured for MT-6345 for the PKPOP subjects in Part 1 and Part 2, and on Day 1 in Part 3.

    Time frame: Part 1 and Part 2: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72 (Day 4), 120 (Day 6), 192 (Day 9), and 336 (Day 15 Follow-up Visit) hours. Part 3: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours.

  4. Area Under the Plasma Concentration Time Curve From Time Zero to 24 Hours (AUC0-24h) of MT-6345

    AUC(0-24h) was computed for MT-6345 for the PKPOP subjects in Part 1 and Part 2, and on Day 1 in Part 3.

    Time frame: Part 1 and Part 2: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72 (Day 4), 120 (Day 6), 192 (Day 9), and 336 (Day 15 Follow-up Visit) hours. Part 3: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours.

  5. Area Under the Plasma Concentration Time Curve From Time Zero to the Last Measurable Concentration (AUC0-last) of MT-6345

    AUC(0-last) was computed for MT-6345 for the PKPOP subjects in Part 1 and Part 2, and on Day 1 in Part 3.

    Time frame: Part 1 and Part 2: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72 (Day 4), 120 (Day 6), 192 (Day 9), and 336 (Day 15 Follow-up Visit) hours. Part 3: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours.

  6. Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-∞) of MT-6345

    AUC(0-∞) was calculated for the PKPOP subjects in Part 1 and Part 2, and on Day 1 in Part 3.

    Time frame: Part 1 and Part 2: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72 (Day 4), 120 (Day 6), 192 (Day 9), and 336 (Day 15 Follow-up Visit) hour. Part 3: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours.

  7. Terminal Elimination Rate Constant (Kel) of MT-6345

    Kel was estimated for the PKPOP subjects in Part 1 and Part 2, and on Day 1 in Part 3.

    Time frame: Part 1 and Part 2: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72 (Day 4), 120 (Day 6), 192 (Day 9), and 336 (Day 15 Follow-up Visit) hours. Part 3: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours.

  8. Mean Residence Time (MRT) of MT-6345

    MRT was calculated for the PKPOP subjects in Part 1 and Part 2, and on Day 1 in Part 3.

    Time frame: Part 1 and Part 2: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72 (Day 4), 120 (Day 6), 192 (Day 9), and 336 (Day 15 Follow-up Visit) hours. Part 3: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours.

  9. Apparent Oral Clearance (CL/F) of MT-6345

    CL/F was measured for MT-6345 in the PKPOP subjects of Part 1 and Part 2, and on Day 1 in Part 3.

    Time frame: Part 1 and Part 2: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72 (Day 4), 120 (Day 6), 192 (Day 9), and 336 (Day 15 Follow-up Visit) hours. Part 3: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours.

  10. Area Under the Plasma Concentration Time Curve Over the Dosing Interval (AUC0-t) of MT-6345.

    Time frame: up to 2 weeks after dosing

  11. Apparent Volume of Distribution at Steady State (Vss/F) of MT-6345

    Vss/F was measured for MT-6345 in the PKPOP subjects of Part 1 and Part 2, and on Day 1 in Part 3.

    Time frame: Part 1 and Part 2: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72 (Day 4), 120 (Day 6), 192 (Day 9), and 336 (Day 15 Follow-up Visit) hours. Part 3: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours.

  12. Linearity Factor (LF) of MT-6345

    Time frame: up to 2 weeks after dosing

  13. Accumulation Ratio (RA) of MT-6345

    Time frame: up to 2 weeks after dosing

  14. Urinary Excreted Amount of Test Compound (Ae) of MT-6345

    Ae was measured for MT-6345 for the PKPOP subjects in Part 3.

    Time frame: Day 1 (0 hours to 24 hours) and Day 10 (0 hours to 24 hours)

  15. Urinary Excreted Amount of Test Compound Expressed as a Percentage of the Dose Administered (Ae%) of MT-6345

    Ae% was measured for MT-6345 for the PKPOP subjects in Part 3.

    Time frame: Day 1 (pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12 and 16 hours) and Day 2 to Day 10 (pre-dose on each day)

  16. Renal Clearance (CLR) of MT-6345

    CLR was measured for MT-6345 for the PKPOP subjects in Part 3. For Day 10, CLR was not calculated because AUC(0-24h) on the last day of dosing was not calculated.

    Time frame: Day 1 (0 hours to 24 hours) and Day 10 (0 hours to 24 hours)

07

Results

Posted Sep 21, 2021

Participant flow

Part 1
Participant flow — Part 1
MilestonePart 1 and Part 2 PlaceboPart 1: MT-6345 1 mgPart 1: MT-6345 5 mgPart 1 and Part 2: MT-6345 20 mgPart 1: MT-6345 60 mgPart 1: MT-6345 120 mgPart 1: MT-6345 240 mgPart 3: PlaceboPart 3: MT-6345 60 mg
Started1166664500
Completed1066564500
Not completed100100000
Withdrew: Withdrawal by subject100100000
Part 2
Participant flow — Part 2
MilestonePart 1 and Part 2 PlaceboPart 1: MT-6345 1 mgPart 1: MT-6345 5 mgPart 1 and Part 2: MT-6345 20 mgPart 1: MT-6345 60 mgPart 1: MT-6345 120 mgPart 1: MT-6345 240 mgPart 3: PlaceboPart 3: MT-6345 60 mg
Started100500000
Completed100500000
Not completed000000000
Part 3
Participant flow — Part 3
MilestonePart 1 and Part 2 PlaceboPart 1: MT-6345 1 mgPart 1: MT-6345 5 mgPart 1 and Part 2: MT-6345 20 mgPart 1: MT-6345 60 mgPart 1: MT-6345 120 mgPart 1: MT-6345 240 mgPart 3: PlaceboPart 3: MT-6345 60 mg
Started000000026
Completed000000000
Not completed000000026
Withdrew: Withdrawn by study termination000000026

Outcome measures

PrimaryNumber of Participants With Mild, Moderate and Severe Adverse Events

The criteria of Mild, Moderate and Severe are as follows: Mild: The event is transient and easily tolerated by the subject. Moderate: The event causes discomfort and interferes with the subject's general condition. Severe: The event causes considerable interference with the subject's general condition and may be incapacitating.

Time frame:
Up to 6 weeks
Reported as:
Number · participants
Number of Participants With Mild, Moderate and Severe Adverse Events
participantsPart 1 PlaceboPart 1: MT-6345 1 mgPart 1: MT-6345 5 mgPart 1: MT-6345 20 mgPart 1: MT-6345 60 mgPart 1: MT-6345 120 mgPart 1: MT-6345 240 mgPart 2: PlaceboPart 2: MT-6345 20 mgPart 3: PlaceboPart 3: MT-6345 60 mg
Mild40212120202
Moderate00001000001
Severe00000000000
SecondaryMaximum Plasma Concentration (Cmax) of MT-6345

Cmax was measured for MT-6345 for the PK analysis set (PKPOP) subjects in Part 1 and Part 2, and on Day 1 in Part 3.

Time frame:
Part 1 and Part 2: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72 (Day 4), 120 (Day 6), 192 (Day 9), and 336 (Day 15 Follow-up Visit) hours. Part 3: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours.
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax) of MT-6345
ng/mLPart 1: MT-6345 1 mgPart 1: MT-6345 5 mgPart 1: MT-6345 20 mgPart 1: MT-6345 60 mgPart 1: MT-6345 120 mgPart 1: MT-6345 240 mgPart 2: MT-6345 20 mgPart 3: MT-6345 60 mg
Maximum Plasma Concentration (Cmax) of MT-63458.219 ± 1.41437.37 ± 9.471153.3 ± 38.85386.2 ± 65.23780.9 ± 118.51522 ± 301.7141.0 ± 42.39523.8 ± 200.7
SecondaryTime to Maximum Plasma Concentration (Tmax) of MT-6345

Tmax was measured for MT-6345 for the PKPOP subjects in Part 1 and Part 2, and on Day 1 in Part 3.

Time frame:
Part 1 and Part 2: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72 (Day 4), 120 (Day 6), 192 (Day 9), and 336 (Day 15 Follow-up Visit) hours. Part 3: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours.
Reported as:
Median · hour
Time to Maximum Plasma Concentration (Tmax) of MT-6345
hourPart 1: MT-6345 1 mgPart 1: MT-6345 5 mgPart 1: MT-6345 20 mgPart 1: MT-6345 60 mgPart 1: MT-6345 120 mgPart 1: MT-6345 240 mgPart 2: MT-6345 20 mgPart 3: MT-6345 60 mg
Time to Maximum Plasma Concentration (Tmax) of MT-63450.75 (0.50 to 1.00)1.01 (1.00 to 1.52)1.00 (0.50 to 2.00)1.50 (0.50 to 2.01)1.50 (0.50 to 1.50)1.50 (1.00 to 1.50)2.00 (0.50 to 5.00)1.25 (0.50 to 2.00)
SecondaryPlasma Terminal Elimination Half Life (t½) of MT-6345

t1/2 was measured for MT-6345 for the PKPOP subjects in Part 1 and Part 2, and on Day 1 in Part 3.

Time frame:
Part 1 and Part 2: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72 (Day 4), 120 (Day 6), 192 (Day 9), and 336 (Day 15 Follow-up Visit) hours. Part 3: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours.
Reported as:
Mean · hour
Plasma Terminal Elimination Half Life (t½) of MT-6345
hourPart 1: MT-6345 1 mgPart 1: MT-6345 5 mgPart 1: MT-6345 20 mgPart 1: MT-6345 60 mgPart 1: MT-6345 120 mgPart 1: MT-6345 240 mgPart 2: MT-6345 20 mgPart 3: MT-6345 60 mg
Plasma Terminal Elimination Half Life (t½) of MT-634534.89 ± 12.5431.83 ± 7.1634.99 ± 8.6944.38 ± 10.7646.03 ± 22.7647.43 ± 31.5839.46 ± 8.9631.09 ± 8.69
SecondaryArea Under the Plasma Concentration Time Curve From Time Zero to 24 Hours (AUC0-24h) of MT-6345

AUC(0-24h) was computed for MT-6345 for the PKPOP subjects in Part 1 and Part 2, and on Day 1 in Part 3.

Time frame:
Part 1 and Part 2: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72 (Day 4), 120 (Day 6), 192 (Day 9), and 336 (Day 15 Follow-up Visit) hours. Part 3: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours.
Reported as:
Mean · ng.h/mL
Area Under the Plasma Concentration Time Curve From Time Zero to 24 Hours (AUC0-24h) of MT-6345
ng.h/mLPart 1: MT-6345 1 mgPart 1: MT-6345 5 mgPart 1: MT-6345 20 mgPart 1: MT-6345 60 mgPart 1: MT-6345 120 mgPart 1: MT-6345 240 mgPart 2: MT-6345 20 mgPart 3: MT-6345 60 mg
Area Under the Plasma Concentration Time Curve From Time Zero to 24 Hours (AUC0-24h) of MT-634559.6 ± 12.6342 ± 89.61350 ± 2934050 ± 8887570 ± 63415100 ± 28301400 ± 2884200 ± 938
SecondaryArea Under the Plasma Concentration Time Curve From Time Zero to the Last Measurable Concentration (AUC0-last) of MT-6345

AUC(0-last) was computed for MT-6345 for the PKPOP subjects in Part 1 and Part 2, and on Day 1 in Part 3.

Time frame:
Part 1 and Part 2: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72 (Day 4), 120 (Day 6), 192 (Day 9), and 336 (Day 15 Follow-up Visit) hours. Part 3: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours.
Reported as:
Mean · ng.h/mL
Area Under the Plasma Concentration Time Curve From Time Zero to the Last Measurable Concentration (AUC0-last) of MT-6345
ng.h/mLPart 1: MT-6345 1 mgPart 1: MT-6345 5 mgPart 1: MT-6345 20 mgPart 1: MT-6345 60 mgPart 1: MT-6345 120 mgPart 1: MT-6345 240 mgPart 2: MT-6345 20 mgPart 3: MT-6345 60 mg
Area Under the Plasma Concentration Time Curve From Time Zero to the Last Measurable Concentration (AUC0-last) of MT-6345115 ± 28.6776 ± 2843060 ± 108011100 ± 259021500 ± 874041200 ± 201003590 ± 12004200 ± 938
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-∞) of MT-6345

AUC(0-∞) was calculated for the PKPOP subjects in Part 1 and Part 2, and on Day 1 in Part 3.

Time frame:
Part 1 and Part 2: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72 (Day 4), 120 (Day 6), 192 (Day 9), and 336 (Day 15 Follow-up Visit) hour. Part 3: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours.
Reported as:
Mean · ng.h/mL
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-∞) of MT-6345
ng.h/mLPart 1: MT-6345 1 mgPart 1: MT-6345 5 mgPart 1: MT-6345 20 mgPart 1: MT-6345 60 mgPart 1: MT-6345 120 mgPart 1: MT-6345 240 mgPart 2: MT-6345 20 mgPart 3: MT-6345 60 mg
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-∞) of MT-6345126 ± 31786 ± 2853190 ± 120011200 ± 264021800 ± 930042200 ± 212003650 ± 12009570 ± 3530
SecondaryTerminal Elimination Rate Constant (Kel) of MT-6345

Kel was estimated for the PKPOP subjects in Part 1 and Part 2, and on Day 1 in Part 3.

Time frame:
Part 1 and Part 2: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72 (Day 4), 120 (Day 6), 192 (Day 9), and 336 (Day 15 Follow-up Visit) hours. Part 3: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours.
Reported as:
Mean · /h
Terminal Elimination Rate Constant (Kel) of MT-6345
/hPart 1: MT-6345 1 mgPart 1: MT-6345 5 mgPart 1: MT-6345 20 mgPart 1: MT-6345 60 mgPart 1: MT-6345 120 mgPart 1: MT-6345 240 mgPart 2: MT-6345 20 mgPart 3: MT-6345 60 mg
Terminal Elimination Rate Constant (Kel) of MT-63450.0222 ± 0.00810.0226 ± 0.00440.0208 ± 0.0050.0166 ± 0.0050.0176 ± 0.00720.0198 ± 0.01040.0182 ± 0.00380.0244 ± 0.0096
SecondaryMean Residence Time (MRT) of MT-6345

MRT was calculated for the PKPOP subjects in Part 1 and Part 2, and on Day 1 in Part 3.

Time frame:
Part 1 and Part 2: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72 (Day 4), 120 (Day 6), 192 (Day 9), and 336 (Day 15 Follow-up Visit) hours. Part 3: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours.
Reported as:
Mean · hour
Mean Residence Time (MRT) of MT-6345
hourPart 1: MT-6345 1 mgPart 1: MT-6345 5 mgPart 1: MT-6345 20 mgPart 1: MT-6345 60 mgPart 1: MT-6345 120 mgPart 1: MT-6345 240 mgPart 2: MT-6345 20 mgPart 3: MT-6345 60 mg
Mean Residence Time (MRT) of MT-634542.1 ± 16.640.8 ± 1043.9 ± 11.957.3 ± 14.558.3 ± 28.658.8 ± 40.650.3 ± 9.5242.5 ± 11.9
SecondaryApparent Oral Clearance (CL/F) of MT-6345

CL/F was measured for MT-6345 in the PKPOP subjects of Part 1 and Part 2, and on Day 1 in Part 3.

Time frame:
Part 1 and Part 2: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72 (Day 4), 120 (Day 6), 192 (Day 9), and 336 (Day 15 Follow-up Visit) hours. Part 3: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours.
Reported as:
Mean · litre per hour
Apparent Oral Clearance (CL/F) of MT-6345
litre per hourPart 1: MT-6345 1 mgPart 1: MT-6345 5 mgPart 1: MT-6345 20 mgPart 1: MT-6345 60 mgPart 1: MT-6345 120 mgPart 1: MT-6345 240 mgPart 2: MT-6345 20 mgPart 3: MT-6345 60 mg
Apparent Oral Clearance (CL/F) of MT-63458.36 ± 1.936.89 ± 1.817.14 ± 2.935.79 ± 2.156.16 ± 2.157.30 ± 4.175.88 ± 1.606.92 ± 2.20
SecondaryArea Under the Plasma Concentration Time Curve Over the Dosing Interval (AUC0-t) of MT-6345.
Time frame:
up to 2 weeks after dosing

No measurements were reported for this outcome.

SecondaryApparent Volume of Distribution at Steady State (Vss/F) of MT-6345

Vss/F was measured for MT-6345 in the PKPOP subjects of Part 1 and Part 2, and on Day 1 in Part 3.

Time frame:
Part 1 and Part 2: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72 (Day 4), 120 (Day 6), 192 (Day 9), and 336 (Day 15 Follow-up Visit) hours. Part 3: Pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours.
Reported as:
Mean · litre(s)
Apparent Volume of Distribution at Steady State (Vss/F) of MT-6345
litre(s)Part 1: MT-6345 1 mgPart 1: MT-6345 5 mgPart 1: MT-6345 20 mgPart 1: MT-6345 60 mgPart 1: MT-6345 120 mgPart 1: MT-6345 240 mgPart 2: MT-6345 20 mgPart 3: MT-6345 60 mg
Apparent Volume of Distribution at Steady State (Vss/F) of MT-6345335 ± 86.7271 ± 60.3286 ± 39.8318 ± 82.4314 ± 32.2319 ± 85.5284 ± 32.6280 ± 82.4
SecondaryLinearity Factor (LF) of MT-6345
Time frame:
up to 2 weeks after dosing

No measurements were reported for this outcome.

SecondaryAccumulation Ratio (RA) of MT-6345
Time frame:
up to 2 weeks after dosing

No measurements were reported for this outcome.

SecondaryUrinary Excreted Amount of Test Compound (Ae) of MT-6345

Ae was measured for MT-6345 for the PKPOP subjects in Part 3.

Time frame:
Day 1 (0 hours to 24 hours) and Day 10 (0 hours to 24 hours)
Reported as:
Mean · milligram(s)
Urinary Excreted Amount of Test Compound (Ae) of MT-6345
milligram(s)Part 3: MT-6345 60 mg
Day 10.160 ± 0.0440
Day 100.255 ± 0.102
SecondaryUrinary Excreted Amount of Test Compound Expressed as a Percentage of the Dose Administered (Ae%) of MT-6345

Ae% was measured for MT-6345 for the PKPOP subjects in Part 3.

Time frame:
Day 1 (pre-dose and post-dose at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12 and 16 hours) and Day 2 to Day 10 (pre-dose on each day)
Reported as:
Mean · percentage of dose
Urinary Excreted Amount of Test Compound Expressed as a Percentage of the Dose Administered (Ae%) of MT-6345
percentage of dosePart 3: MT-6345 60 mg
Day 10.3 ± 0.1
Day 100.4 ± 0.2
SecondaryRenal Clearance (CLR) of MT-6345

CLR was measured for MT-6345 for the PKPOP subjects in Part 3. For Day 10, CLR was not calculated because AUC(0-24h) on the last day of dosing was not calculated.

Time frame:
Day 1 (0 hours to 24 hours) and Day 10 (0 hours to 24 hours)
Reported as:
Mean · L/h
Renal Clearance (CLR) of MT-6345
L/hPart 3: MT-6345 60 mg
Renal Clearance (CLR) of MT-63450.0390 ± 0.0110

Adverse events

Collected over From the time written informed consent was obtained from a subject until the end of the Follow-up Period or the withdrawal from the study were recorded, up to 6 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1 Placebo0/11 (0%)0/11 (0%)4/11 (36.4%)
Part 1: MT-6345 1 mg0/6 (0%)0/6 (0%)0/6 (0%)
Part 1: MT-6345 5 mg0/6 (0%)0/6 (0%)2/6 (33.3%)
Part 1: MT-6345 20 mg0/6 (0%)0/6 (0%)1/6 (16.7%)
Part 1: MT-6345 60 mg0/6 (0%)0/6 (0%)2/6 (33.3%)
Part 1: MT-6345 120 mg0/4 (0%)0/4 (0%)1/4 (25%)
Part 1: MT-6345 240 mg0/5 (0%)0/5 (0%)2/5 (40%)
Part 2: Placebo0/1 (0%)0/1 (0%)0/1 (0%)
Part 2: MT-6345 20 mg0/5 (0%)0/5 (0%)2/5 (40%)
Part 3: Placebo0/2 (0%)0/2 (0%)0/2 (0%)
Part 3: MT-6345 60 mg0/6 (0%)0/6 (0%)2/6 (33.3%)
Most frequent other events
Showing 10 of 20
Most frequent other events
EventPart 1 PlaceboPart 1: MT-6345 1 mgPart 1: MT-6345 5 mgPart 1: MT-6345 20 mgPart 1: MT-6345 60 mgPart 1: MT-6345 120 mgPart 1: MT-6345 240 mgPart 2: PlaceboPart 2: MT-6345 20 mgPart 3: PlaceboPart 3: MT-6345 60 mg
HeadacheNervous system disorders1/110/60/61/61/60/41/50/10/50/22/6
Back painMusculoskeletal and connective tissue disorders0/110/60/60/60/61/40/50/10/50/20/6
Skin abrasionInjury, poisoning and procedural complications0/110/60/60/60/60/40/50/11/50/20/6
NauseaGastrointestinal disorders0/110/60/60/61/60/41/50/10/50/21/6
HaematuriaRenal and urinary disorders0/110/60/60/60/60/41/50/10/50/20/6
ErythemaSkin and subcutaneous tissue disorders0/110/60/60/60/60/40/50/11/50/20/6
PetechiaeSkin and subcutaneous tissue disorders0/110/60/60/60/60/40/50/11/50/20/6
Medical device site reactionGeneral disorders1/110/61/60/60/60/40/50/10/50/20/6
Blood creatine phosphokinase increasedInvestigations0/110/61/60/60/60/40/50/10/50/20/6
TachycardiaCardiac disorders0/110/60/60/61/60/40/50/10/50/20/6

Baseline characteristics

The analysis population is the subjects of Part 1 and Part 3 since the subjects of part 2 were selected from part 1.

Age, Customized
Age, Customized(Participants)Part 1 PlaceboPart 1: MT-6345 1 mgPart 1: MT-6345 5 mgPart 1: MT-6345 20 mgPart 1: MT-6345 60 mgPart 1: MT-6345 120 mgPart 1: MT-6345 240 mgPart 3 PlaceboPart 3: MT-6345 60 mgTotal
18-64 years116666452652
Sex: Female, Male
Sex: Female, Male(Participants)Part 1 PlaceboPart 1: MT-6345 1 mgPart 1: MT-6345 5 mgPart 1: MT-6345 20 mgPart 1: MT-6345 60 mgPart 1: MT-6345 120 mgPart 1: MT-6345 240 mgPart 3 PlaceboPart 3: MT-6345 60 mgTotal
Female0000000000
Male116666452652
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1 PlaceboPart 1: MT-6345 1 mgPart 1: MT-6345 5 mgPart 1: MT-6345 20 mgPart 1: MT-6345 60 mgPart 1: MT-6345 120 mgPart 1: MT-6345 240 mgPart 3 PlaceboPart 3: MT-6345 60 mgTotal
Hispanic or Latino0000000000
Not Hispanic or Latino116666452652
Unknown or Not Reported0000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1 PlaceboPart 1: MT-6345 1 mgPart 1: MT-6345 5 mgPart 1: MT-6345 20 mgPart 1: MT-6345 60 mgPart 1: MT-6345 120 mgPart 1: MT-6345 240 mgPart 3 PlaceboPart 3: MT-6345 60 mgTotal
American Indian or Alaska Native0000000000
Asian0000000000
Native Hawaiian or Other Pacific Islander0000000000
Black or African American0000000000
White116666452652
More than one race0000000000
Unknown or Not Reported0000000000
08

Study locations

1 site
  • Investigational center
    City Name, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Jul 2019, 5 months.

Results were first posted in Sep 2021, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2019
First posted
Jan 18, 2019
StartActual
Jan 15, 2019
Primary completionActual
Jul 1, 2019
CompletionActual
Jul 1, 2020
Results first posted
Sep 21, 2021
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03809039
Responsible party
Sponsor
First posted
Jan 18, 2019
Start date
Jan 15, 2019
Primary completion
Jul 1, 2019
Completion
Jul 1, 2020
Results posted
Sep 21, 2021
Last update
Dec 31, 2025

Study contacts

Head of Medical Science,
study director · Tanabe Pharma America, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion